CW Advisors LLC Takes Position in Alphatec Holdings, Inc. $ATEC

Key Points

• CW Advisors LLC acquired 92,828 shares of Alphatec Holdings, Inc. (NASDAQ: ATEC), valued at approximately $941,000, during the first quarter of the year.
• Alphatec reported a quarterly earnings per share (EPS) of $0.02, exceeding analysts' expectations of (-$0.06), with revenue of $185.54 million.
• Currently, 66.35% of Alphatec's stock is owned by institutional investors, and several analysts have recently reiterated a "buy" rating on the company's shares.

CW Advisors LLC acquired a new position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 92,828 shares of the medical technology company's stock, valued at approximately $941,000. CW Advisors LLC owned 0.06% of Alphatec at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Lido Advisors LLC lifted its position in Alphatec by 8.4% during the fourth quarter. Lido Advisors LLC now owns 12,247 shares of the medical technology company's stock valued at $112,000 after purchasing an additional 953 shares during the period. Comerica Bank lifted its position in Alphatec by 66.8% during the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 1,248 shares during the period. Oppenheimer Asset Management Inc. lifted its position in Alphatec by 13.4% during the first quarter. Oppenheimer Asset Management Inc. now owns 13,144 shares of the medical technology company's stock valued at $133,000 after purchasing an additional 1,552 shares during the period. Mercer Global Advisors Inc. ADV lifted its position in Alphatec by 0.6% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 288,967 shares of the medical technology company's stock valued at $2,653,000 after purchasing an additional 1,784 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Alphatec by 4.6% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 40,734 shares of the medical technology company's stock valued at $413,000 after purchasing an additional 1,792 shares during the period. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Alphatec

In other Alphatec news, COO Scott Lish sold 36,081 shares of the business's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $12.53, for a total value of $452,094.93. Following the transaction, the chief operating officer directly owned 708,855 shares in the company, valued at $8,881,953.15. The trade was a 4.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel Tyson Eliot Marshall sold 18,092 shares of the business's stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $14.91, for a total transaction of $269,751.72. Following the completion of the sale, the general counsel directly owned 438,331 shares in the company, valued at $6,535,515.21. This trade represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 410,247 shares of company stock worth $5,376,804 in the last ninety days. 22.80% of the stock is owned by insiders.

Alphatec Price Performance

Shares of ATEC stock traded down $0.13 on Friday, reaching $15.90. 1,651,222 shares of the company were exchanged, compared to its average volume of 2,698,129. The company has a market cap of $2.35 billion, a price-to-earnings ratio of -14.07 and a beta of 1.02. The business has a 50-day moving average price of $12.88 and a 200 day moving average price of $11.74. The company has a debt-to-equity ratio of 23.22, a quick ratio of 1.77 and a current ratio of 2.88. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $16.47.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.08. The firm had revenue of $185.54 million for the quarter, compared to analyst estimates of $178.85 million. Alphatec had a negative net margin of 24.33% and a negative return on equity of 1,657.19%. Alphatec's quarterly revenue was up 27.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.29) earnings per share. Alphatec has set its FY 2025 guidance at EPS. Equities research analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ATEC shares. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a report on Friday, August 1st. Lake Street Capital raised shares of Alphatec to a "buy" rating and set a $18.00 price objective for the company in a report on Monday, June 16th. Barclays reaffirmed an "overweight" rating and issued a $22.00 price objective (up previously from $21.00) on shares of Alphatec in a report on Monday, August 4th. Finally, Wall Street Zen cut shares of Alphatec from a "buy" rating to a "hold" rating in a report on Saturday. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $18.50.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.